Work

ASO Author Reflections: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma

Year: 2025

Type: article

Abstract: Recent clinical trials have reported superior outcomes using neoadjuvant immunotherapy compared with surgery followed by adjuvant immunotherapy alone for resectable patients with clinical stage III/IV melanoma, with practicechanging clinical implications.1,2 However, investigation into the optimal agent and dosing schedule is ongoing.

Source: Annals of Surgical Oncology

DOI: 10.1245/s10434-025-18456-6

Authors: Mohammad Saad Farooq, Neha Shafique, Giorgos C. Karakousis

Institutions: Hospital of the University of Pennsylvania, University of Pennsylvania

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,590